苏州君境生物医药科技

Suzhou Junjing Biopharmaceutical Technology is a Chinese biotechnology company focused on the research and development of antiviral therapeutics. Established as a joint venture involving Junshi Biosciences and Vigonvita Life Sciences, the company is best known for its lead product, Mindevir (VV116), an oral nucleoside analog for the treatment of COVID-19. Mindevir targets the RNA-directed RNA polymerase (RdRp) and has demonstrated efficacy in clinical trials, leading to its conditional marketing approval by the NMPA in China. The company operates primarily within the Suzhou Industrial Park, benefiting from the region's robust life sciences ecosystem. Junjing Bio continues to collaborate with academic and industrial partners to expand its portfolio of anti-infective agents.